Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology - Reuters
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQbUNLeXg3N3k2RHR6T1ozbUI0MFd3ekE1YS1sNmxuWjZxeDhSZ1lDb1NqWXBsbXRaMktEcWV6b3dKREtyMEVCcy12dlI3cGtoVk1xYUFVbjVsNXVyclRIVXdvMFBWZG1UN21JLUZkcVpEZjdvbjRlU3YzUS1hd2xqYzJSZVFSZF9LVVBtY01Demh0U094NzE4a0xtaUNONHlqcTVqZWlybGdYYWlEVzlpaHFJZV80NkY2N1NQR1E2a1FIaFRwT3c?oc=5" target="_blank">Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AMMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMSanofi to pay Regeneron $1 billion upfront in expanded immunology deal - Reuters
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Reuters
October 1, 2026 at 05:17 AMBayer to invest $2.2 billion in new US pharma site - Reuters
Bayer to invest $2.2 billion in new US pharma site Reuters
October 2, 2026 at 07:19 PMAstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Reuters
September 28, 2026 at 10:15 PMBioNTech to shutter three sites in Germany as no buyers emerge - Reuters
BioNTech to shutter three sites in Germany as no buyers emerge Reuters
September 28, 2026 at 08:00 PM